scholarly journals Regression of prostate tumors upon combination of hormone ablation therapy and celecoxib in vivo

The Prostate ◽  
2010 ◽  
Vol 71 (8) ◽  
pp. 813-823 ◽  
Author(s):  
Parisa Abedinpour ◽  
Véronique T. Baron ◽  
John Welsh ◽  
Per Borgström
Keyword(s):  
Prostate Tumors ◽  
Ablation Therapy ◽  
Hormone Ablation ◽  
Hormone Ablation Therapy

scholarly journals Dietary n-3 Polyunsaturated Fatty Acids Enhance Hormone Ablation Therapy in Androgen-Dependent Prostate Cancer

2008 ◽  
Vol 173 (1) ◽  
pp. 229-241 ◽  
Author(s):  
Michael F. McEntee ◽  
Carol Ziegler ◽  
Danielle Reel ◽  
Kenneth Tomer ◽  
Ahmed Shoieb ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Fatty Acids ◽  
Polyunsaturated Fatty Acids ◽  
Ablation Therapy ◽  
Hormone Ablation ◽  
Hormone Ablation Therapy

scholarly journals Pharmacotherapy Options in Cancer Treatment-induced Bone Loss: Focus on Bisphosphonates

2009 ◽  
Vol 1 ◽  
pp. CMT.S2064
Author(s):  
Kouta Ito
Keyword(s):  
Breast Cancer ◽  
Prostate Cancer ◽  
Bone Loss ◽  
Cancer Survivors ◽  
Cancer Treatment ◽  
Small Sample ◽  
Ablation Therapy ◽  
Prostate Cancer Survivors ◽  
Hormone Ablation ◽  
Hormone Ablation Therapy

Bone loss and its associated risk of fracture is a serious long-term health issue for breast cancer and prostate cancer survivors. Hormone ablation therapy, in particular aromatase inhibitors (AIs) for breast cancer and androgen deprivation therapy (ADT) for prostate cancer, causes marked reduction in circulating estrogen or testosterone levels, resulting in increased bone resorption, decreased bone mineral density (BMD), and an increased risk of fragility fracture. In several clinical trials with small sample sizes and short follow-up periods, oral and intravenous bisphosphonates have been shown to improve BMD, but not actual fracture rates, in cancer patients on hormone ablation therapy. A number of professional organizations and expert panels recommend the use of bisphosphonates for selected patients at risk. Although bisphosphonates are generally well tolerated, physicians should be aware of safety concerns, including the risk of osteonecrosis of the jaw. With the growing number of older breast and prostate cancer survivors, additional research is needed to characterize patients who would benefit from pharmacotherapy and optimize strategies to prevent cancer treatment-induced bone loss.

scholarly journals Treatment-Induced Bone Loss and Fractures in Cancer Patients Undergoing Hormone Ablation Therapy: Efficacy and Safety of Denosumab

2012 ◽  
Vol 6 ◽  
pp. CMO.S8511 ◽  
Author(s):  
Allan Lipton ◽  
Matthew R. Smith ◽  
Georgiana K. Ellis ◽  
Carsten Goessl
Keyword(s):  
Prostate Cancer ◽  
Bone Mass ◽  
Human Monoclonal Antibody ◽  
Osteoclast Formation ◽  
Mineral Density ◽  
Ablation Therapy ◽  
Markers Of Bone Turnover ◽  
Hormone Ablation ◽  
And Function ◽  
Hormone Ablation Therapy

Hormone ablation therapy (HALT) for breast or prostate cancer accelerates the development of osteoporosis in both men and women by causing estrogen deficiency, which increases the risk for fracture by promoting bone resorption mediated by osteoclasts. Denosumab, a fully human monoclonal antibody that inhibits osteoclast formation and function, increases bone mass in patients undergoing hormone ablation therapy. In the HALT study of 1,468 men with prostate cancer on androgen-deprivation therapy, denosumab significantly reduced the risk of new vertebral fractures, increased bone mineral density (BMD), and reduced markers of bone turnover. In a study of 252 women with breast cancer undergoing adjuvant aromatase inhibitor (AI) therapy, denosumab increased BMD at 12 and 24 months, overall and in all patient subgroups. The overall rates of adverse events were similar to placebo. Clinicians should consider fracture risk assessment and therapies such as denosumab to increase bone mass in patients on hormone ablation therapy who are at high risk for fracture.

Effect of castration on endothelin receptors

2002 ◽  
Vol 103 (s2002) ◽  
pp. 442S-445S ◽  
Author(s):  
Robert J. PADLEY ◽  
Douglas B. DIXON ◽  
J. Ruth WU-WONG
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Receptor Expression ◽  
Growth Disorders ◽  
Binding Studies ◽  
Ablation Therapy ◽  
Significant Difference ◽  
Hormone Ablation ◽  
Hormone Refractory ◽  
Hormone Ablation Therapy

Endothelin (ET) plays a pivotal role in the pathogenesis of cell growth disorders such as cancer. Atrasentan (ABT-627), a selective antagonist for the ET receptor A (ETA), has shown benefit in controlling disease progression in men with hormone refractory prostate cancer who have undergone aggressive hormone ablation therapy. It is not known how hormone ablation affects ET-binding sites, although ET-1 and ETA expression are found to be elevated in prostate cancer patients. In this study, we examined the effect of castration on ET receptor binding in male beagle dogs. Three dogs were surgically castrated and another three sham-operated. The animals were sacrificed 1 week after operation and membranes were prepared from the prostate, heart, brain, kidney, liver and lung for ET-1, ET-3 and angiotensin II (A-II, as a control) binding studies. No significant difference in A-II binding was observed between castrated and sham-operated animals. However, ET-1 and ET-3 binding to prostate and brain membranes were altered significantly. From saturation binding studies using ET-1 in the prostate, the Kd and Bmax values increased from 0.043nM and 0.094pmol/mg respectively in sham-operated dogs to 0.104nM and 0.311pmol/mg respectively in castrated animals. These results indicate that surgical castration in dogs produces a change in the ET receptor density in the prostate and brain, and may have implications for the effect of hormone ablation therapy on ET receptor expression in prostate cancer patients.

scholarly journals Hyperspectral Imagery for Assessing Laser-Induced Thermal State Change in Liver

Sensors ◽  
2021 ◽  
Vol 21 (2) ◽  
pp. 643
Author(s):  
Martina De Landro ◽  
Ignacio Espíritu García-Molina ◽  
Manuel Barberio ◽  
Eric Felli ◽  
Vincent Agnus ◽  
...  
Keyword(s):  
Thermal Damage ◽  
Thermal State ◽  
Preliminary Investigation ◽  
Spectral Band ◽  
Spectral Variation ◽  
Ablation Therapy ◽  
Clinical Endpoints ◽  
Breathing Motion ◽  
Living Tissues

This work presents the potential of hyperspectral imaging (HSI) to monitor the thermal outcome of laser ablation therapy used for minimally invasive tumor removal. Our main goal is the establishment of indicators of the thermal damage of living tissues, which can be used to assess the effect of the procedure. These indicators rely on the spectral variation of temperature-dependent tissue chromophores, i.e., oxyhemoglobin, deoxyhemoglobin, methemoglobin, and water. Laser treatment was performed at specific temperature thresholds (from 60 to 110 °C) on in-vivo animal liver and was assessed with a hyperspectral camera (500–995 nm) during and after the treatment. The indicators were extracted from the hyperspectral images after the following processing steps: the breathing motion compensation and the spectral and spatial filtering, the selection of spectral bands corresponding to specific tissue chromophores, and the analysis of the areas under the curves for each spectral band. Results show that properly combining spectral information related to deoxyhemoglobin, methemoglobin, lipids, and water allows for the segmenting of different zones of the laser-induced thermal damage. This preliminary investigation provides indicators for describing the thermal state of the liver, which can be employed in the future as clinical endpoints of the procedure outcome.

scholarly journals Targeted gold nanoparticles enhance sensitization of prostate tumors to megavoltage radiation therapy in vivo

2015 ◽  
Vol 11 (5) ◽  
pp. 1277-1283 ◽  
Author(s):  
Tatiana Wolfe ◽  
Dev Chatterjee ◽  
Jihyoun Lee ◽  
Jonathan D. Grant ◽  
Shanta Bhattarai ◽  
...  
Keyword(s):  
Gold Nanoparticles ◽  
Radiation Therapy ◽  
Prostate Tumors
Sign in / Sign up

Export Citation Format

Share Document